

Effects of blackcurrant extract on arterial functions in older adults: A randomized, double-blind, placebo-controlled, crossover trial

Journal:	<i>Clinical and Experimental Hypertension</i>
Manuscript ID	LCEH-2020-0069
Manuscript Type:	Original Papers
Date Submitted by the Author:	09-Mar-2020
Complete List of Authors:	Okamoto, Takanobu; Nippon Sport Science University, Department of Exercise Physiology Hashimoto, Yuto; Nippon Sport Science University, Graduate School of Health and Sport Science Kobayashi, Ryota; Teikyo University of Science, Center for Fundamental Education Nakazato, Koichi; Nippon Sport Science University, Department of Exercise Physiology Willems, Mark ; University of Chichester, Institute of Sport
Keywords:	Anthocyanins, Pulse wave velocity, Augmentation index, Vascular function, Cardiovascular risk factors

SCHOLARONE™
Manuscripts

Clinical and Experimental Hypertension

Original Papers

Effects of blackcurrant extract on arterial functions in older adults: A randomized, double-blind, placebo-controlled, crossover trial

Running Head: Blackcurrant extract on arterial functions

Takanobu Okamoto, PhD, Yuto Hashimoto, MS, Ryota Kobayashi, PhD, Koichi Nakazato, PhD, Mark Elisabeth Theodorus Willems, PhD

Takanobu Okamoto, PhD, Yuto Hashimoto, MS, Koichi Nakazato, PhD

Department of Exercise Physiology, Nippon Sport Science University, Tokyo, Japan

Ryota Kobayashi, PhD

Center for Fundamental Education, Teikyo University of Science, Tokyo, Japan

Mark Elisabeth Theodorus Willems, PhD

Institute of Sport, University of Chichester, Chichester, United Kingdom

Corresponding author

Takanobu Okamoto

ORCID ID: 0000-0003-1978-2455

7-1-1, Fukasawa, Setagaya-ku, Tokyo, 158-8508, Japan

Tel: +81-3-5706-0966

Fax: +81-3-5706-0966

e-mail: tokamoto@nittai.ac.jp

ABSTRACT

Purpose: Blackcurrant extract mainly contains anthocyanins. Several reports suggest that anthocyanins have beneficial effect for cardiovascular functions. The aim of this study was to examine the effect of 7-day intake of New Zealand blackcurrant (NZBC) extract on arterial functions, e.g. arterial stiffness, and serum lipids.

Methods: A randomized, double-blind, placebo-controlled, crossover design study with a washout period of 28 days was conducted. Fourteen older adults participated in this study (age 73.3 ± 1.7 years). Participants took either a 7-day course of placebo or two capsules of NZBC extract (each 300 mg capsule contains 35% blackcurrant extract). Participants took one of the two trials first and then took the other after a washout period. Carotid-femoral pulse-wave velocity, an index of central arterial stiffness, and central blood pressure were measured at baseline and again at the end of the 7-day study period.

Results: Compared to baseline, carotid-femoral pulse-wave velocity ($P = 0.03$) and central blood pressure ($P = 0.02$) decreased significantly after the 7-day study period with NZBC intake. In addition, carotid-femoral pulse-wave velocity ($P = 0.04$) and central blood pressure ($P = 0.001$) in the NZBC intake trial decreased significantly more than in the placebo intake trial. No effects were observed on serum lipids.

Conclusion: These results suggest that short-term NZBC intake reduces central arterial stiffness and central blood pressure in older adults. Therefore, anthocyanin-rich blackcurrants

1
2
3
4 42 might be beneficial for maintaining or improving cardiovascular health as an alternative to
5
6
7 43 pharmaceutical medications.
8
9

10 44
11
12

13 45 **Key words:** Anthocyanins, Pulse wave velocity, Augmentation index, Vascular function,
14
15
16 46 Cardiovascular risk factors
17
18

19 47
20
21

22 48 **Abbreviations**
23
24

25 49 AIx, augmentation index; BP, blood pressure; cfPWV, carotid–femoral pulse-wave velocity;
26
27

28 50 CVD, cardiovascular diseases; DBP, diastolic blood pressure; faPWV, femoral-ankle pulse-
29
30

31 51 wave velocity; FG, fasting glucose; HDL, high-density lipoprotein cholesterol; LDL, low-
32
33

34 52 density lipoprotein cholesterol; MBP, mean blood pressure; NZBC, New Zealand blackcurrant;
35
36

37 53 PP, pulse pressure, SBP, systolic blood pressure; TG, triglycerides
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Mortality due to cardiovascular disease is a serious global problem (1), and many strategies are needed to prevent cardiovascular disease. An increase in central arterial stiffness as assessed by carotid-femoral pulse wave velocity (cfPWV) is a powerful predictor of future cardiovascular events, such as myocardial infarction or stroke, and all-cause mortality (2-4). In addition, central aortic blood pressure (BP) has greater prognostic capability than brachial BP, and is more strongly related to vascular hypertrophy, the extent of atherosclerosis, and other cardiovascular events (3-6). Therefore, minimizing increases in central arterial stiffness and central BP are important for the prevention of cardiovascular disease (CVD).

In previous randomized trials, it has been reported that consumption of polyphenols from foods or extracts significantly improved vascular health. In fact, polyphenol-rich foods such as berries, chocolate, or cocoa reduced brachial BP or central arterial stiffness and improved vascular endothelial function (7,8). Prospective studies investigating the association between flavonoid consumption and myocardial infarction risk in young and middle-aged adults showed that high intake of anthocyanins present in blueberries and strawberries is associated with a decreased risk of myocardial infarction (9). Anthocyanins are among the polyphenols that are part of the flavonoid family. Anthocyanins have potent antioxidant capacity and/or a powerful vasodilator effect by producing nitric oxide (10-13). It is known that short-term anthocyanin consumption significantly reduces arterial stiffness and improves

1
2
3
4 73 vascular endothelial function compared to placebo in young and middle-aged adults (14-17).
5
6
7 74 In addition, according to a meta-analysis by Fairlie-Jones et al.(18) acute intake of anthocyanin
8
9
10 75 significantly improved arterial stiffness in healthy young adults. On the other hand,
11
12
13 76 blackcurrants include specific anthocyanins, consisting primarily of delphinidin-3-rutinoside,
14
15
16 77 delphinidin-3-glucoside, cyanidin-3-rutinoside, and cyanidin-3-glucoside, which have
17
18
19 78 numerous health benefits (19,20). Thus, intake of anthocyanin-rich blackcurrants may have a
20
21
22 79 number of beneficial effects on cardiovascular health. However, to the best of our knowledge,
23
24
25 80 the effects of short-term blackcurrant consumption on central arterial stiffness and central BP
26
27
28 81 in older adults are unknown. More research is needed to determine various strategies to achieve
29
30
31 82 cardioprotective effects in older adults.
32
33

34 83 The aim of this study was to examine the effect of 7-day intake of New Zealand
35
36
37 84 blackcurrant (NZBC) extract on arterial functions, such as arterial stiffness and serum lipids.
38
39
40 85 We hypothesized that short-term NZBC intake reduces central arterial stiffness and blood
41
42
43 86 pressure in older adults.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 106 committee of Nippon Sport Science University (Japan) (018-H087).
5
6

7 107
8
9

10 108 **Schedule**
11
12

13 109 Participants visited the laboratory four times at the same time in the morning (8:00
14
15
16 110 am). Figure 2 shows the experimental schedule. Before arrival, participants were instructed to
17
18
19 111 avoid vigorous exercise for 48 hours, alcohol for 24 hours and caffeine-containing products on
20
21
22 112 the day of testing and be fasted for at least 10–14 hours overnight.
23
24

25 113 At every visit, arterial stiffness and BP were measured and blood samples collected
26
27
28 114 from the ulnar vein of the nondominant arm of each participant.
29
30

31 115
32
33

34 116 **NZBC and placebo intake**
35
36

37 117 Participants ingested 2 × 300 mg capsules (total 210 mg of anthocyanins) of
38
39
40 118 concentrated NZBC extract or a visually identical placebo for 7 days. Each 300 mg NZBC
41
42
43 119 capsule contained 105 mg of anthocyanins, consisting of 35–50% delphinidin-3-rutinoside, 5–
44
45
46 120 20% delphinidin-3-glucoside, 30–45% cyanidin-3-rutinoside, and 3–10% cyanidin-3-
47
48
49 121 glucoside (CurraNZ®, Health Currancy Ltd., Surrey, UK). Each placebo capsule contained
50
51
52 122 300 mg microcrystalline cellulose. Two capsules were consumed with breakfast for the first 6
53
54
55 123 days. On the final morning of the supplementation period, participants were instructed to take
56
57
58 124 the supplement or placebo without breakfast, with the last intake about 2 h before an
59
60

1
2
3
4 125 experimental visit. The two experimental conditions (NZBC extract and placebo) were
5
6
7 126 separated by a 4-week washout period (21). Intake of beverages such as green tea and/or dietary
8
9
10 127 supplements that included polyphenols were prohibited during the study. No restrictions were
11
12
13 128 placed on food intake, but all participants were instructed to maintain their normal diet and
14
15
16 129 lifestyle throughout the study period.

17
18
19 130

22 131 **Body composition**

23
24
25 132 The body composition of the participants was determined by bioelectric impedance
26
27
28 133 using a body-composition analyzer (InBody770, Biospace Co Ltd, Seoul, South Korea).

29
30
31 134

34 135 **Arterial stiffness**

35
36
37 136 cfPWV and femoral–ankle PWV (faPWV), which reflect aortic and leg arterial
38
39
40 137 stiffness, respectively, were measured. Carotid and femoral artery-pressure waveforms were
41
42
43 138 obtained for 30 seconds using arterial applanation tonometry incorporating form PWV/ABI
44
45
46 139 micropiezoresistive transducers (Omron-Colin Co Ltd, Tokyo, Japan), which comprise 15
47
48
49 140 aligned pressure-sensitive elements that can identify carotid and femoral pulse traces, arranged
50
51
52 141 side by side and attached to the left common carotid and femoral arteries, respectively. A
53
54
55 142 vascular testing device (form PWV/ABI; Omron-Colin) was used to measure simultaneously
56
57
58 143 electrocardiograms, bilateral brachial and ankle BP, and carotid-arterial and femoral-arterial

1
2
3
4 144 pulse waves (PWs). cfPWV and faPWV were calculated by dividing the distance between the
5
6
7 145 two arterial recording sites by the transit time, which is determined based on the time delay
8
9
10 146 between the proximal and distal “foot” waveforms. faPWV is calculated based on the transit
11
12
13 147 time between the femoral artery site and the ankle site. Next, time delays were obtained from
14
15
16 148 between the right brachial and posttibial arteries, the carotid and femoral arteries (Tcf), and the
17
18
19 149 femoral and posttibial arteries. A nonelastic tape measure was then used to make duplicate
20
21
22 150 random zero-length measurements over the body surface in order to determine the path length
23
24
25 151 from the carotid to the femoral artery (Dcf). cfPWV was calculated using the following
26
27
28 152 equation:

31 153

$$34 \text{ 154 } \text{cfPWV} = \text{Dcf}/\text{Tcf}$$

37 155

40 156 The investigator who performed the PWV measurements was blinded to the condition
41
42
43 157 assignment of the participants.
44
45

46 158

49 159 **Central and brachial BPs and the augmentation index (AIx)**

52 160 Arterial pulse waveforms of the left radial artery for estimating central BP were
53
54
55 161 measured non-invasively by an automated tonometric system (HEM-9000AI, Omron
56
57
58 162 Healthcare Co., Ltd.). Central BP and the AIx were measured as previously described (22,23).
59
60

1
2
3
4 163 Brachial BP was measured with an oscillometric manometer, and radial pulse waveforms were
5
6
7 164 recorded non-invasively using an applanation tonometer. Signals of the radial arterial pressure
8
9
10 165 wave were low-pass-filtered, first at a cut-off frequency of 105 Hz to remove high-frequency
11
12
13 166 noise and then at 25 Hz to extract pressure waveforms. Inflection points or peaks that
14
15
16 167 corresponded to first (early) and second (late) systolic BP were automatically identified using
17
18
19 168 the fourth derivative wave as the second and third zero crossing points, respectively. Late SBP
20
21
22 169 in the radial artery was used as an estimate of the central SBP and was calculated using the
23
24
25 170 following equation:

$$26$$
$$27$$
$$28 \text{Late SBP} = (P2/PP) \times (\text{SBP} - \text{DBP}) + \text{DBP}$$
$$29$$
$$30$$

31 172 In addition, the radial AIx was calculated using the following equation:

$$32$$
$$33$$
$$34 \text{AIx}(\%) = (P2/PP) \times 100$$
$$35$$
$$36$$

37 174 where P2 is the pressure difference between the peak systolic pressure and an early inflection
38
39
40 175 point that indicates the beginning upstroke of the reflected pressure wave, and PP is the pulse
41
42
43 176 pressure.

44
45
46 177 The AIx was adjusted for a heart rate of 75 bpm (AIx@75).

47
48
49 178 In addition, mean brachial BP (MBP) and brachial pulse pressure (PP) were calculated
50
51
52 179 using the following equations:

$$53$$
$$54$$
$$55 \text{MBP} = [\text{DBP} + (\text{SBP} - \text{DBP}) / 3].$$
$$56$$

$$57$$
$$58 \text{PP} = \text{SBP} - \text{DBP}$$
$$59$$
$$60$$

182

183 Serum lipids profile and glucose

184 Whole blood was drawn into serum separator tubes, allowed to clot and centrifuged at
185 4,000 RCF for 15 minutes. Triglyceride (TG), high-density lipoprotein cholesterol (HDL-C),
186 low-density lipoprotein cholesterol (LDL-C) and fasting glucose (FG) in blood samples were
187 measured using standard enzymatic techniques. The intra- and interassay coefficients of
188 variance was less than 5%.

189

190 Statistics

191 All data are expressed as means \pm standard error. Statistical analyses were performed
192 using statistical software (SPSS ver. 24; SPSS, Inc., Chicago, IL, USA). The assumption of a
193 normal distribution for all data was verified using the Kolmogorov–Smirnov test, and all data
194 were normally distributed. Data were analyzed using two-way analysis of variance (trials \times
195 periods) with repeated measures. When the main effect or interaction was significant, the paired
196 t-test was used to identify significant differences among the mean values. Statistical
197 significance was set at $P < 0.05$. In addition, The interpretation of p as $0.05 > p \leq 0.1$ was
198 according to guidelines by Curran-Everett and Benos (24).

RESULTS

Figure 3 shows changes in cfPWV before and after both NZBC and placebo. The cfPWV at baseline did not differ significantly between NZBC and placebo. cfPWV decreased significantly after NZBC intake compared with baseline values ($P = 0.03$). In contrast, the cfPWV did not differ significantly between before and after placebo intake. Significant differences in cfPWV were observed between the NZBC and placebo after intervention ($P = 0.04$).

Figure 4 shows changes in central BP before and after both NZBC and placebo. The central BP at baseline did not differ significantly between NZBC and placebo. Central BP decreased significantly after NZBC intake compared with baseline values ($P = 0.02$). In contrast, the central BP did not differ significantly before and after placebo intake. Significant differences in central BP were observed between the NZBC and placebo after intervention ($P = 0.001$).

Table 2 shows changes in brachial SBP, DBP, MBP, PP, AIx, and faPWV before and after NZBC and placebo. The brachial SBP, DBP, MBP, PP, AIx, and faPWV at baseline did not differ significantly between NZBC and placebo. Brachial SBP ($P = 0.03$), DBP ($P = 0.02$), MBP ($P = 0.01$), and AIx ($P = 0.03$) decreased significantly after NZBC intake compared with baseline values. PP had a tendency to decrease after NZBC intake compared with baseline values ($P = 0.09$). In contrast, brachial SBP, DBP, MBP, PP and AIx did not differ significantly

1
2
3
4 218 between before and after placebo intake. Significant differences in brachial SBP ($P = 0.001$),
5
6
7 219 MBP ($P = 0.01$), PP ($P = 0.01$), and AIx ($P = 0.01$) were observed between the NZBC and
8
9
10 220 placebo trials after intervention ($P = 0.001$). There was a trend for DBP to be lower with NZBC
11
12
13 221 trial compared with placebo trial after intervention ($p = 0.07$). On the other hand, faPWV did
14
15
16 222 not differ significantly between before and after both NZBC and placebo. In addition, no
17
18
19 223 significant differences in faPWV were observed between the NZBC and placebo trials after
20
21
22 224 intervention.

25 225 Table 3 shows changes in serum lipids profile before and after both NZBC and placebo.
26
27
28 226 No significant differences were seen between NZBC and placebo in serum concentrations of
29
30
31 227 TG, HDL-C, LDL-C, or FG at baseline. No significant changes were observed between the two
32
33
34 228 trials in serum concentrations of TG, HDL-C, LDL-C, or FG after both NZBC and placebo.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 229 **DISCUSSION**

5
6
7 230 The key finding of this study was that 7 days intake of anthocyanin-rich NZBC in
8
9
10 231 older adults decreased cfPWV and cSBP with no changes in the placebo condition. These
11
12
13 232 results suggest that short-term intake of NZBC would decrease central arterial stiffness and BP
14
15
16 233 in older adults.

17
18
19 234 An increase in central arterial stiffness and/or central BP has been shown to be
20
21
22 235 independently associated with future cardiovascular events, such as myocardial infarction or
23
24
25 236 stroke, and all-cause mortality (25,26). Therefore, intake of NZBC may be an important type
26
27
28 237 of non-pharmacological therapy to enhance cardiovascular health in older adults.

29
30
31 238 The present findings show for the first time that anthocyanin-rich foods such as NZBC
32
33
34 239 reduce arterial stiffness in older adults. Anthocyanins are flavonoids, all of which are phenolic
35
36
37 240 compounds (i.e., polyphenols). Recent studies have shown that ingestion of anthocyanins-rich
38
39
40 241 foods, including black currants, blueberries, grapes, and purple potatoes, have the beneficial
41
42
43 242 effects of reducing arterial stiffness in both young and middle-aged adults, and growing
44
45
46 243 evidence highlights that specific flavonoids from plant bioactive compounds present in fruits
47
48
49 244 improve vascular function (27,28). Some previous studies that examined the associations
50
51
52 245 between anthocyanin intake and arterial stiffness focused predominantly on young and middle-
53
54
55 246 aged participants. In our recent study, it was shown that intake of polyphenol-rich cocoa
56
57
58 247 reduced cfPWV in postmenopausal women (8). In addition, previous studies showed an

1
2
3
4 248 association between polyphenol-rich food intake and decreased aortic stiffness in healthy adults,
5
6
7 249 independent of age (3,4,29,30). Consistent with previous studies (8,31), the present results
8
9
10 250 suggest that intake of polyphenol-rich foods, i.e. anthocyanin-rich blackcurrant, improves
11
12
13 251 central arterial stiffness. Thus, the present findings expand on previous research on the effects
14
15
16 252 of polyphenol-rich foods on arterial stiffness in older adults.

17
18
19 253 In addition to the improvements in central arterial stiffness, 7-day intake of NZBC
20
21
22 254 extract was shown, for the first time, to reduce central BP by average of 10 mmHg, which
23
24
25 255 appears to be a better predictor of cardiovascular events than brachial BP (3-6). Wang et al.
26
27
28 256 (32) observed central BP reductions of 6 mmHg that reduced cardiovascular mortality by
29
30
31 257 approximately 25%. Thus, the present findings showed that NZBC intake reduced central BP,
32
33
34 258 suggesting the effectiveness of anthocyanin-rich foods for reducing central BP.

35
36
37 259 In the previous meta-analyses of randomized controlled trials, consumption of
38
39
40 260 flavonoid-rich foods (e.g., green tea, soy protein isolates, and cocoa or chocolate) was shown
41
42
43 261 to reduce peripheral (brachial) BP (33). Consistent with a previous study, the present findings
44
45
46 262 showed that intake of NZBC reduced brachial BP. Moreover, NZBC intake reduced the AIX.
47
48
49 263 The central aortic pressure wave consists of a forward traveling wave generated by left
50
51
52 264 ventricular ejection, followed by a later-arriving reflected wave from the periphery (34). In
53
54
55 265 addition, as arterial stiffness increases, central BP increases can occur due to increased forward
56
57
58 266 and reflected wave amplitudes and earlier return of the reflected wave to the proximal aorta.

1
2
3
4 267 Reduction in the AIx is associated with increased peripheral vasodilation (35), caused by
5
6
7 268 decreased wave reflection at medium-sized muscular arteries (36). Therefore, the decreased
8
9
10 269 AIx in the present study may have been caused by peripheral vasodilation. Moreover, the
11
12
13 270 measurements of arterial stiffness obtained from non-invasive pressure waveforms suggested
14
15
16 271 that decreased aortic stiffness is associated with reduced AIx (37). Thus, the present findings
17
18
19 272 suggest that the changes in central arterial stiffness and BP after NZBC intake were primarily
20
21
22 273 the result of changes in arterial distension. Aortic stiffness affects both early systolic cardiac
23
24
25 274 load, through elevation of the forward pressure wave, and late systolic cardiac load, due to
26
27
28 275 earlier return of the reflected pressure wave (38-42). Thus, the present findings suggested that
29
30
31 276 the effect of NZBC intake was mediated by reductions in both early systolic and late systolic
32
33
34 277 pressures, suggesting decreased aortic stiffness and arteriolar tone, respectively. Therefore,
35
36
37 278 since decreased wave reflection decreases LV afterload and myocardial oxygen demand (43),
38
39
40 279 NZBC intake appears to be effective for reducing cardiovascular risk in older adults.

41
42
43 280 In the present study, there were no differences in serum lipids and glucose after intake
44
45
46 281 of NZBC or placebo. Alvarez-Suarez et al. (44) reported that one-month intake of anthocyanin-
47
48
49 282 rich strawberry improved the lipid profile by significantly reducing TC, LDL-C, and TG levels
50
51
52 283 compared to baseline levels, while no changes were seen in HDL cholesterol. In this respect,
53
54
55 284 the present results differ from that of previous study. One possible reason for this difference
56
57
58 285 may be differences in the subjects and intake duration among studies. Moreover, since TC,
59
60

1
2
3
4 286 LDL-C, and TG in most participants of the present study were within the standard ranges, their
5
6
7 287 values might not have differed from baseline values. In addition, Tsang et al. (28) reported that
8
9
10 288 intake of an anthocyanin-rich potato did not change glucose. This result is consistent with our
11
12
13 289 findings. Thus, the present findings showed that NZBC intake did not change serum lipid
14
15
16 290 profile and glucose in older adults.

17
18
19 291 In individuals at risk, medical and pharmacologic interventions can decrease
20
21
22 292 cardiovascular mortality, but such interventions are costly and may have adverse effects
23
24
25 293 (45,46). In contrast, in epidemiological studies, higher anthocyanin intake was associated with
26
27
28 294 decreased arterial stiffness and BP (47,48). Increased arterial stiffness or BP is a major CVD
29
30
31 295 risk factor (49), which, when decreased significantly, reduces the risk of CVD and death in
32
33
34 296 various populations (50). Various fruits, vegetables, and beverages that are commonly
35
36
37 297 consumed in the human diet can be rich in anthocyanins (51-53) Therefore, the present findings
38
39
40 298 emphasize the importance of incorporating more anthocyanin-rich foods, including fruits and
41
42
43 299 vegetables and berries such as NZBC, which promote cardiovascular health without side effects.

44
45
46 300 This study has some limitations. First, the short time frame of the study might have
47
48
49 301 prevented observation of the benefits of longer-term consumption on arterial stiffness and BP.
50
51
52 302 Second, vascular endothelial function, antioxidant capabilities, and inflammatory markers were
53
54
55 303 not measured. Third, the results in this study population of healthy older adults might not be
56
57
58 304 generalizable to CVD patients. Finally, there was no information on anthocyanin-derived
59
60

1
2
3
4 305 metabolites with 7-day NZBC intake. Nevertheless, to the best of our knowledge, the present
5
6
7 306 data provide the first evidence that short-term intake of NZBC may contribute to reductions in
8
9
10 307 central arterial stiffness and BP in older adults. Further long-term, randomized, interventional
11
12
13 308 studies are needed to establish the role of NZBC in supporting cardiovascular health in older
14
15
16 309 adults.

17
18
19 310

20 21 22 311 **Conclusion**

23
24
25 312 In conclusion, the findings of the present study indicate that short-term NZBC intake
26
27
28 313 reduces central arterial stiffness and BP in older adults. These results suggest that habitual
29
30
31 314 NZBC intake may be an effective way to prevent CVD. Therefore, anthocyanin-rich
32
33
34 315 blackcurrants might be beneficial for maintaining or improving cardiovascular health as an
35
36
37 316 alternative to pharmaceutical medications.

38
39
40 317

41 42 43 318 **Acknowledgement**

44
45
46 319 The authors would like to thank Mr. Hiroyuki Hatakeyama for technical assistance
47
48
49 320 with the experiments.

50
51
52 321

53 54 55 322 **Funding**

56
57
58 323 There are no funding sources for the present study.

1
2
3
4 324

5
6
7 325 **Compliance with ethical standards**

8
9
10 326 **Conflict of interest**

11
12
13 327 The authors have no conflict of interest to declare.

14
15
16 328 **Statement of human and animal rights**

17
18
19 329 This study was approved by the Ethics Committee of Nippon Sport Science University.

20
21
22 330 **Informed consent**

23
24
25 331 Informed consent was obtained from all participants.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

332 **REFERENCES**

- 333 1. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-
334 cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic
335 analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117-
336 71. DOI:10.1016/S0140-6736(14)61682-2 PMID:PMC4340604.
- 337 2. Scuteri A, Tesauro M, Appolloni S, Preziosi F, Brancati AM, Volpe M. Arterial
338 stiffness as an independent predictor of longitudinal changes in cognitive function in
339 the older individual. *J Hypertens*. 2007;25(5):1035-40.
340 DOI:10.1097/HJH.0b013e3280895b55
- 341 3. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C.
342 Prediction of cardiovascular events and all-cause mortality with central
343 haemodynamics: a systematic review and meta-analysis. *Eur Heart J*.
344 2010;31(15):1865-71. DOI:10.1093/eurheartj/ehq024
- 345 4. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and
346 all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am*
347 *Coll Cardiol*. 2010;55(13):1318-27. DOI:10.1016/j.jacc.2009.10.061
- 348 5. Cheng HM, Chuang SY, Sung SH, Yu WC, Pearson A, Lakatta EG, Pan WH, Chen
349 CH. Derivation and validation of diagnostic thresholds for central blood pressure
350 measurements based on long-term cardiovascular risks. *J Am Coll Cardiol*.

- 1
2
3
4 351 2013;62(19):1780-7. DOI:10.1016/j.jacc.2013.06.029 PMID:PMC3884552.
5
6
7 352 6. Safar ME, Levy BI. Studies on arterial stiffness and wave reflections in hypertension.
8
9
10 353 Am J Hypertens. 2015;28(1):1-6. DOI:10.1093/ajh/hpu155
11
12
13 354 7. Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, Cassidy A. Effects
14
15
16 355 of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and
17
18
19 356 meta-analysis of randomized trials. Am J Clin Nutr. 2012;95(3):740-51.
20
21
22 357 DOI:10.3945/ajcn.111.023457
23
24
25 358 8. Okamoto T, Kobayashi R, Natsume M, Nakazato K. Habitual cocoa intake reduces
26
27
28 359 arterial stiffness in postmenopausal women regardless of intake frequency: a
29
30
31 360 randomized parallel-group study. Clin Interv Aging. 2016;11:1645-1652.
32
33
34 361 DOI:10.2147/CIA.S118152 PMID:PMC5115689.
35
36
37 362 9. Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB. High anthocyanin
38
39
40 363 intake is associated with a reduced risk of myocardial infarction in young and middle-
41
42
43 364 aged women. Circulation. 2013;127(2):188-96.
44
45
46 365 DOI:10.1161/CIRCULATIONAHA.112.122408 PMID:PMC3762447.
47
48
49 366 10. Edirisinghe I, Banaszewski K, Cappozzo J, McCarthy D, Burton-Freeman BM. Effect
50
51
52 367 of black currant anthocyanins on the activation of endothelial nitric oxide synthase
53
54
55 368 (eNOS) in vitro in human endothelial cells. J Agric Food Chem. 2011;59(16):8616-24.
56
57
58 369 DOI:10.1021/jf201116y
59
60

- 1
2
3
4 370 11. Edirisinghe I, Banaszewski K, Cappozzo J, Sandhya K, Ellis CL, Tadapaneni R,
5
6
7 371 Kappagoda CT, Burton-Freeman BM. Strawberry anthocyanin and its association with
8
9
10 372 postprandial inflammation and insulin. *Br J Nutr.* 2011;106(6):913-22.
11
12
13 373 DOI:10.1017/S0007114511001176
14
15
16 374 12. Wallace TC. Anthocyanins in cardiovascular disease. *Adv Nutr.* 2011;2(1):1-7.
17
18
19 375 DOI:10.3945/an.110.000042 PMCID:PMC3042791.
20
21
22 376 13. Zafra-Stone S, Yasmin T, Bagchi M, Chatterjee A, Vinson JA, Bagchi D. Berry
23
24
25 377 anthocyanins as novel antioxidants in human health and disease prevention. *Mol Nutr*
26
27
28 378 *Food Res.* 2007;51(6):675-83. DOI:10.1002/mnfr.200700002
29
30
31 379 14. Keane KM, George TW, Constantinou CL, Brown MA, Clifford T, Howatson G.
32
33
34 380 Effects of Montmorency tart cherry (*Prunus Cerasus L.*) consumption on vascular
35
36
37 381 function in men with early hypertension. *Am J Clin Nutr.* 2016;103(6):1531-9.
38
39
40 382 DOI:10.3945/ajcn.115.123869
41
42
43 383 15. Rodriguez-Mateos A, Feliciano RP, Boeres A, Weber T, Dos Santos CN, Ventura MR,
44
45
46 384 Heiss C. Cranberry (poly)phenol metabolites correlate with improvements in vascular
47
48
49 385 function: A double-blind, randomized, controlled, dose-response, crossover study. *Mol*
50
51
52 386 *Nutr Food Res.* 2016;60(10):2130-2140. DOI:10.1002/mnfr.201600250
53
54
55 387 16. Rodriguez-Mateos A, Rendeiro C, Bergillos-Meca T, Tabatabaee S, George TW, Heiss
56
57
58 388 C, Spencer JP. Intake and time dependence of blueberry flavonoid-induced
59
60

- 1
2
3
4 389 improvements in vascular function: a randomized, controlled, double-blind, crossover
5
6
7 390 intervention study with mechanistic insights into biological activity. *Am J Clin Nutr.*
8
9
10 391 2013;98(5):1179-91. DOI:10.3945/ajcn.113.066639
11
12
13 392 17. Zhu Y, Xia M, Yang Y, Liu F, Li Z, Hao Y, Mi M, Jin T, Ling W. Purified anthocyanin
14
15
16 393 supplementation improves endothelial function via NO-cGMP activation in
17
18
19 394 hypercholesterolemic individuals. *Clin Chem.* 2011;57(11):1524-33.
20
21
22 395 DOI:10.1373/clinchem.2011.167361
23
24
25 396 18. Fairlie-Jones L, Davison K, Fromentin E, Hill AM. The Effect of Anthocyanin-Rich
26
27
28 397 Foods or Extracts on Vascular Function in Adults: A Systematic Review and Meta-
29
30
31 398 Analysis of Randomised Controlled Trials. *Nutrients.* 2017;9(8).
32
33
34 399 DOI:10.3390/nu9080908 PMID:PMC5579701.
35
36
37 400 19. Gavrilova V, Kajdzanoska M, Gjamovski V, Stefova M. Separation, characterization
38
39
40 401 and quantification of phenolic compounds in blueberries and red and black currants by
41
42
43 402 HPLC-DAD-ESI-MSn. *J Agric Food Chem.* 2011;59(8):4009-18.
44
45
46 403 DOI:10.1021/jf104565y
47
48
49 404 20. Gopalan A, Reuben SC, Ahmed S, Darvesh AS, Hohmann J, Bishayee A. The health
50
51
52 405 benefits of blackcurrants. *Food Funct.* 2012;3(8):795-809. DOI:10.1039/c2fo30058c
53
54
55 406 21. Jin Y, Alimbetov D, George T, Gordon MH, Lovegrove JA. A randomised trial to
56
57
58 407 investigate the effects of acute consumption of a blackcurrant juice drink on markers of
59
60

- 1
2
3
4 408 vascular reactivity and bioavailability of anthocyanins in human subjects. *Eur J Clin*
5
6
7 409 *Nutr.* 2011;65(7):849-56. DOI:10.1038/ejcn.2011.55
8
9
10 410 22. Kumagai H, Zempo-Miyaki A, Yoshikawa T, Tsujimoto T, Tanaka K, Maeda S.
11
12
13 411 Lifestyle modification increases serum testosterone level and decrease central blood
14
15
16 412 pressure in overweight and obese men. *Endocr J.* 2015;62(5):423-30.
17
18
19 413 DOI:10.1507/endocrj.EJ14-0555
20
21
22 414 23. Tanaka S, Sugiura T, Yamashita S, Dohi Y, Kimura G, Ohte N. Differential response
23
24
25 415 of central blood pressure to isometric and isotonic exercises. *Sci Rep.* 2014;4:5439.
26
27
28 416 DOI:10.1038/srep05439 PMCID:PMC4069636.
29
30
31 417 24. Curran-Everett D, Benos DJ. Guidelines for reporting statistics in journals published
32
33
34 418 by the American Physiological Society. *Am J Physiol Regul Integr Comp Physiol.*
35
36
37 419 2004;287(2):R247-9. DOI:10.1152/ajpregu.00346.2004
38
39
40 420 25. Karras A, Haymann JP, Bozec E, Metzger M, Jacquot C, Maruani G, Houillier P,
41
42
43 421 Froissart M, Stengel B, Guardiola P, Laurent S, Boutouyrie P, Briet M, Nephro Test
44
45
46 422 Study G. Large artery stiffening and remodeling are independently associated with all-
47
48
49 423 cause mortality and cardiovascular events in chronic kidney disease. *Hypertension.*
50
51
52 424 2012;60(6):1451-7. DOI:10.1161/HYPERTENSIONAHA.112.197210
53
54
55 425 26. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA,
56
57
58 426 Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham
59
60

- 1
2
3
4 427 Heart Study. Circulation. 2010;121(4):505-11.
5
6
7 428 DOI:10.1161/CIRCULATIONAHA.109.886655 PMID:PMC2836717.
8
9
10 429 27. Rodriguez-Mateos A, Heiss C, Borges G, Crozier A. Berry (poly)phenols and
11
12 cardiovascular health. J Agric Food Chem. 2014;62(18):3842-51.
13 430
14
15 431 DOI:10.1021/jf403757g
16
17
18 432 28. Tsang C, Smail NF, Almoosawi S, McDougall GJM, Al-Dujaili EAS. Antioxidant Rich
19
20 Potato Improves Arterial Stiffness in Healthy Adults. Plant Foods Hum Nutr.
21 433
22
23 2018;73(3):203-208. DOI:10.1007/s11130-018-0673-2 PMID:PMC6096904.
24 434
25
26
27 435 29. Grassi D, Desideri G, Necozone S, di Giosia P, Barnabei R, Allegaert L, Bernaert H,
28
29 Ferri C. Cocoa consumption dose-dependently improves flow-mediated dilation and
30 436
31
32 arterial stiffness decreasing blood pressure in healthy individuals. J Hypertens.
33 437
34
35 2015;33(2):294-303. DOI:10.1097/HJH.0000000000000412
36 438
37
38
39 439 30. Heiss C, Sansone R, Karimi H, Krabbe M, Schuler D, Rodriguez-Mateos A, Kraemer
40
41 T, Cortese-Krott MM, Kuhnle GG, Spencer JP, Schroeter H, Merx MW, Kelm M,
42 440
43
44 Flaviola Consortium EUtFP. Impact of cocoa flavanol intake on age-dependent
45 441
46
47 vascular stiffness in healthy men: a randomized, controlled, double-masked trial. Age
48 442
49
50 (Dordr). 2015;37(3):9794. DOI:10.1007/s11357-015-9794-9 PMID:PMC4444618.
51 443
52
53
54 444 31. Vlachopoulos CV, Alexopoulos NA, Aznaouridis KA, Ioakeimidis NC, Dima IA,
55
56
57 Dagre A, Vasiliadou C, Stefanadi EC, Stefanadis CI. Relation of habitual cocoa
58 445
59
60

- 1
2
3
4 446 consumption to aortic stiffness and wave reflections, and to central hemodynamics in
5
6
7 447 healthy individuals. *Am J Cardiol.* 2007;99(10):1473-5.
8
9
10 448 DOI:10.1016/j.amjcard.2006.12.081
11
12
13 449 32. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, Yin FC, Chou
14
15
16 450 P, Chen CH. Central or peripheral systolic or pulse pressure: which best relates to target
17
18
19 451 organs and future mortality? *J Hypertens.* 2009;27(3):461-7. PMID:PMC3178100.
20
21
22 452 33. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL,
23
24
25 453 Cassidy A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis
26
27
28 454 of randomized controlled trials. *Am J Clin Nutr.* 2008;88(1):38-50.
29
30
31 455 DOI:10.1093/ajcn/88.1.38
32
33
34 456 34. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical
35
36
37 457 applications of arterial stiffness; definitions and reference values. *Am J Hypertens.*
38
39
40 458 2002;15(5):426-44.
41
42
43 459 35. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol,
44
45
46 460 not atenolol, reduces wave reflection. *Am J Hypertens.* 2008;21(6):663-7.
47
48
49 461 DOI:10.1038/ajh.2008.156
50
51
52 462 36. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The
53
54
55 463 influence of heart rate on augmentation index and central arterial pressure in humans. *J*
56
57
58 464 *Physiol.* 2000;525 Pt 1:263-70. PMID:PMC2269933.
59
60

- 1
2
3
4 465 37. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive
5
6
7 466 pressure waveforms. *Am J Hypertens.* 2005;18(1 Pt 2):3S-10S.
8
9
10 467 DOI:10.1016/j.amjhyper.2004.10.009
11
12
13 468 38. Borlaug BA, Melenovsky V, Redfield MM, Kessler K, Chang HJ, Abraham TP, Kass
14
15
16 469 DA. Impact of arterial load and loading sequence on left ventricular tissue velocities in
17
18
19 470 humans. *J Am Coll Cardiol.* 2007;50(16):1570-7. DOI:10.1016/j.jacc.2007.07.032
20
21
22 471 39. Chirinos JA, Segers P, Raina A, Saif H, Swillens A, Gupta AK, Townsend R, Emmi
23
24
25 472 AG, Jr., Kirkpatrick JN, Keane MG, Ferrari VA, Wiegers SE, St John Sutton MG.
26
27
28 473 Arterial pulsatile hemodynamic load induced by isometric exercise strongly predicts
29
30
31 474 left ventricular mass in hypertension. *Am J Physiol Heart Circ Physiol.*
32
33
34 475 2010;298(2):H320-30. DOI:10.1152/ajpheart.00334.2009
35
36
37 476 40. Chirinos JA, Segers P, Rietzschel ER, De Buyzere ML, Raja MW, Claessens T, De
38
39
40 477 Bacquer D, St John Sutton M, Gillebert TC, Asklepios I. Early and late systolic wall
41
42
43 478 stress differentially relate to myocardial contraction and relaxation in middle-aged
44
45
46 479 adults: the Asklepios study. *Hypertension.* 2013;61(2):296-303.
47
48
49 480 DOI:10.1161/HYPERTENSIONAHA.111.00530
50
51
52 481 41. Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in
53
54
55 482 human hypertension. *Hypertension.* 2007;49(6):1202-6.
56
57
58 483 DOI:10.1161/HYPERTENSIONAHA.106.076166
59
60

- 1
2
3
4 484 42. Ooi H, Chung W, Biolo A. Arterial stiffness and vascular load in heart failure. *Congest*
5
6
7 485 *Heart Fail.* 2008;14(1):31-6.
8
9
10 486 43. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective.
11
12
13 487 *J Am Coll Cardiol.* 2007;50(1):1-13. DOI:10.1016/j.jacc.2006.12.050
14
15
16 488 44. Alvarez-Suarez JM, Giampieri F, Tulipani S, Casoli T, Di Stefano G, Gonzalez-
17
18
19 489 Paramas AM, Santos-Buelga C, Busco F, Quiles JL, Cordero MD, Bompadre S,
20
21
22 490 Mezzetti B, Battino M. One-month strawberry-rich anthocyanin supplementation
23
24
25 491 ameliorates cardiovascular risk, oxidative stress markers and platelet activation in
26
27
28 492 humans. *J Nutr Biochem.* 2014;25(3):289-94. DOI:10.1016/j.jnutbio.2013.11.002
29
30
31 493 45. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of
32
33
34 494 stroke associated with asymptomatic severe carotid stenosis: results of a systematic
35
36
37 495 review and analysis. *Stroke.* 2009;40(10):e573-83.
38
39
40 496 DOI:10.1161/STROKEAHA.109.556068
41
42
43 497 46. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular
44
45
46 498 diseases: a practical evidence-based approach. *Mayo Clin Proc.* 2009;84(8):741-57.
47
48
49 499 DOI:10.1016/S0025-6196(11)60525-9 PMID:PMC2719528.
50
51
52 500 47. Cassidy A, O'Reilly EJ, Kay C, Sampson L, Franz M, Forman JP, Curhan G, Rimm
53
54
55 501 EB. Habitual intake of flavonoid subclasses and incident hypertension in adults. *Am J*
56
57
58 502 *Clin Nutr.* 2011;93(2):338-47. DOI:10.3945/ajcn.110.006783 PMID:PMC3021426.
59
60

- 1
2
3
4 503 48. Jennings A, Welch AA, Fairweather-Tait SJ, Kay C, Minihane AM, Chowienczyk P,
5
6
7 504 Jiang B, Cecelja M, Spector T, Macgregor A, Cassidy A. Higher anthocyanin intake is
8
9
10 505 associated with lower arterial stiffness and central blood pressure in women. *Am J Clin*
11
12
13 506 *Nutr.* 2012;96(4):781-8. DOI:10.3945/ajcn.112.042036
14
15
16 507 49. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-
17
18
19 508 specific relevance of usual blood pressure to vascular mortality: a meta-analysis of
20
21
22 509 individual data for one million adults in 61 prospective studies. *Lancet.*
23
24
25 510 2002;360(9349):1903-13.
26
27
28 511 50. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J,
29
30
31 512 Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular
32
33
34 513 disease and death: a systematic review and meta-analysis. *Lancet.*
35
36
37 514 2016;387(10022):957-967. DOI:10.1016/S0140-6736(15)01225-8
38
39
40 515 51. Giampieri F, Forbes-Hernandez TY, Gasparrini M, Alvarez-Suarez JM, Afrin S,
41
42
43 516 Bompadre S, Quiles JL, Mezzetti B, Battino M. Strawberry as a health promoter: an
44
45
46 517 evidence based review. *Food Funct.* 2015;6(5):1386-98. DOI:10.1039/c5fo00147a
47
48
49 518 52. Thompson K, Pederick W, Santhakumar AB. Anthocyanins in obesity-associated
50
51
52 519 thrombogenesis: a review of the potential mechanism of action. *Food Funct.*
53
54
55 520 2016;7(5):2169-78. DOI:10.1039/c6fo00154h
56
57
58 521 53. Weh KM, Aiyer HS, Howell AB, Kresty LA. Cranberry proanthocyanidins modulate
59
60

- 1
2
3
4 522 reactive oxygen species in Barrett's and esophageal adenocarcinoma cell lines. J Berry
5
6
7 523 Res. 2016;6(2):125-136. DOI:10.3233/JBR-160122 PMID:PMC5002987.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

1
2
3
4 **525 Figure legends**

5
6
7 526 Figure 1. Consort flow diagram of the participants

8
9
10 527 Figure 2. Experimental schedule

11
12
13 528 Figure 3. Changes in cfPWV before and after both NZBC and placebo

14
15
16 529 *: significantly ($P < 0.05$) different from before.

17
18
19 530 †: significantly ($P < 0.05$) different from placebo.

20
21
22 531 cfPWV, carotid-femoral pulse wave velocity; NZBC, New Zealand blackcurrants

23
24
25 532 Figure 4. Changes in central BP before and after both NZBC and placebo

26
27
28 533 *: significantly ($P < 0.05$) different from before.

29
30
31 534 ††: significantly ($P < 0.01$) different from placebo.

32
33
34 535 SBP, systolic blood pressure; NZBC, New Zealand blackcurrants

536 Table 1. Physical characteristics of the participants

7	Sex (F/M)	8/6
10	Age (years)	73.3±1.7
13	Height (cm)	159.9±2.5
16	Weight (kg)	55.6±2.9
19	Body mass index (kg/m ²)	21.6±0.7
22	Body fat (%)	25.7±1.7

537 Values are mean ± SEM.

538 Table 2. Brachial SBP, DBP, MBP, PP, AIx, and faPWV before and after NZBC and placebo

	NZBC		Placebo	
	Before	After	Before	After
Brachial SBP (mmHg)	142±5	133±3*,††	140±5	142±4
Brachial DBP (mmHg)	79±3	76±2*,‡	79±3	79±3
Brachial MBP (mmHg)	100±3	95±3**,††	98±3	100±3
Brachial PP (mmHg)	63±4	58±2#, †	60±3	63±3
AIx (%)	87±4	83±3*,†	89±3	86±3
faPWV (cm/sec)	1239±49	1186±50	1234±55	1214±44

539 Values are mean ± SEM. *: significantly (P<0.05) difference from before. **: significantly

540 (P<0.01) difference from before. #: denotes a strong trend for a different from baseline (p =

541 0.09). †: significantly (P<0.05) difference from the placebo. ††: significantly (P<0.01)

542 difference from the placebo. ‡: Denotes a strong trend for a different between NZBC and

543 placebo trials (p = 0.07).

544 SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; PP,

545 pulse pressure; AIx, augmentation index; faPWV, femoral-ankle pulse wave velocity; NZBC,

546 New Zealand blackcurrant

547 Table 3. Serum Lipids profile and glucose before and after NZBC and placebo

	NZBC		Placebo	
	Before	After	Before	After
TG (mg/dL)	88±12	85±8	95±10	93±10
HDL-C (mg/dL)	73±5	76±4	71±6	74±5
LDL-C (mg/dL)	124±10	120±8	127±7	127±5
FG (mg/dL)	91±4	91±3	92±4	91±4

548 Values are mean ± SEM. NZBC, New Zealand blackcurrant; TG, triglycerides; HDL-C, high-
549 density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FG, fasting
550 glucose

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 1

Figure 1. Consort flow diagram of the participants

52x69mm (300 x 300 DPI)




Fig. 2

Figure 2. Experimental schedule

52x69mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 3

Figure 3. Changes in cfPWV before and after both NZBC and placebo
52x69mm (300 x 300 DPI)




Fig. 4

Figure 4. Changes in central BP before and after both NZBC and placebo

52x69mm (300 x 300 DPI)